Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs.

Trial Profile

Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Risperidone (Primary) ; Antipsychotics
  • Indications Attention deficit and disruptive behaviour disorders; Autistic disorder; Bipolar disorders; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Feb 2012 Actual number pf patients changed from 241 to 244 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top